Skip to content
July 30, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Kanker Payudara

Kanker Payudara

Primary Menu
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Watch
  • Home
  • Chemotherapy and Targeted Therapy
  • WTWH Media Rebrands as Arrowfly: A New Chapter for the B2B Media Powerhouse
  • Chemotherapy and Targeted Therapy

WTWH Media Rebrands as Arrowfly: A New Chapter for the B2B Media Powerhouse

Nana July 30, 2026 7 minutes read
wtwh-media-rebrands-as-arrowfly-a-new-chapter-for-the-b2b-media-powerhouse

By Editorial Staff

In a major strategic evolution within the B2B media landscape, the Cleveland-based media and marketing firm formerly known as WTWH Media officially announced on July 13, 2026, that it has rebranded as Arrowfly. The corporate transformation, which signals a new era of growth and consolidation, encompasses the parent entity of more than 40 leading B2B media brands, including Drug Discovery & Development (DDD).

While the corporate masthead has shifted to Arrowfly, the company has emphasized that its operational autonomy remains unchanged. Drug Discovery & Development, along with the company’s extensive portfolio of digital platforms, newsletters, and archives, will retain its existing branding, editorial leadership, and digital presence. This move is designed to provide a cohesive corporate identity for a rapidly expanding organization that bridges the gap between complex engineering, life sciences, and industrial technology.


Main Facts: What Changes and What Stays the Same

The transition to Arrowfly is primarily a structural and brand alignment initiative. For the readers of Drug Discovery & Development, the day-to-day experience remains uninterrupted.

  • Corporate Identity: The parent organization is now Arrowfly.
  • Operational Continuity: Drug Discovery & Development maintains its name, URL, editorial staff, and historical archives.
  • Organizational Scope: Arrowfly continues to operate over 40 B2B media brands and more than 45 industry events.
  • Market Presence: The firm maintains its core operational networks: Engineering; Healthcare and Life Sciences; and Food, Retail, and Hospitality.

The rebranding represents a shift in corporate nomenclature intended to reflect a modern, forward-thinking trajectory while honoring the deep-rooted editorial trust the company has cultivated over its years in the industry.


Chronology: A Path of Strategic Growth

The emergence of Arrowfly did not occur in a vacuum; it is the culmination of a multi-year strategy aimed at dominating the B2B information sector. To understand the transition, one must look at the timeline of the company’s development:

2022: The Strategic Inflection Point

The groundwork for this rebrand was laid in 2022 when the company entered into a significant strategic partnership with Mountaingate Capital. This infusion of capital and expertise allowed the organization to pursue a more aggressive acquisition strategy, particularly in the healthcare and life sciences sectors.

2025: Leadership Transition

The appointment of Matt Logan as CEO in 2025 marked a pivotal moment for the company. A B2B media veteran with over 25 years of industry experience, Logan was tasked with streamlining the company’s diverse portfolio and preparing the organization for a unified future. Under his guidance, the focus shifted toward integrating the company’s various acquisitions into a more powerful, singular identity.

2026: The Launch of Arrowfly

On July 13, 2026, the company officially retired the "WTWH Media" name. This date represents the transition from a collection of acquired brands to a cohesive, unified powerhouse positioned for the next decade of media innovation.


Supporting Data: The Scale of the Enterprise

Arrowfly operates at an industrial scale that few B2B media firms can match. By diversifying its reach across three distinct but often overlapping networks, the firm has insulated itself against sector-specific volatility while maximizing cross-industry synergy.

The Network Structure

  • Engineering: This segment covers design, manufacturing, and advanced technology, providing the technical intelligence necessary for modern infrastructure and production.
  • Healthcare and Life Sciences: Home to Drug Discovery & Development, this segment serves a critical ecosystem including medical device manufacturing, health systems, senior care, and behavioral health.
  • Food, Retail, and Hospitality: This segment captures the logistics, consumer-facing technology, and operational insights for the service industry.

The Event-Driven Model

Beyond digital content and newsletters, Arrowfly manages over 45 industry events annually. These gatherings are not merely conferences; they are high-level networking hubs that facilitate the exchange of goods and services between buyers and sellers who might otherwise never interact. This "ecosystem approach" is the primary value proposition that has allowed the company to thrive where traditional trade publishers have struggled.

Drug Discovery & Development parent company WTWH Media is now Arrowfly

Official Responses: The Philosophy of Authority

In his inaugural statement as CEO of the newly branded Arrowfly, Matt Logan addressed the necessity of the change, framing it as an evolution of the company’s core mission rather than a pivot in strategy.

"We built this company by earning the trust of professionals in industries where editorial authority matters," Logan said. "The name is new, but the foundation is the same: editors who speak each industry’s language, events that connect buyers and sellers who would never meet otherwise, and communities that professionals rely on for the insight and intelligence they need to make real decisions."

Logan’s emphasis on "editorial authority" is telling. In an age of AI-generated content and fragmented information, Arrowfly is positioning its human-led, industry-specific expertise as its most durable competitive advantage. The leadership team believes that by consolidating under the Arrowfly name, they can more effectively project this authority to investors, partners, and the global professional communities they serve.


Implications: What This Means for the Future

The rebranding to Arrowfly carries significant implications for the B2B media market, particularly regarding how information is consumed in the life sciences sector.

1. Consolidation and Authority

By moving away from a name that functioned largely as an acronym, Arrowfly is signaling its intent to become a recognizable consumer-facing brand for professionals. This move helps streamline corporate communication and makes it easier for the firm to market its wide array of products under a singular, powerful umbrella.

2. Doubling Down on Niche Intelligence

The persistence of Drug Discovery & Development as a distinct entity within the network suggests that Arrowfly understands the value of niche, high-expertise content. While the parent company has expanded, it has not diluted the quality of its specialized editorial teams. This suggests that the company will continue to acquire or launch niche platforms that require deep technical knowledge.

3. Data-Driven Media

As the industry moves toward more complex data analysis, including NLP (Natural Language Processing) and predictive analytics, the parent company’s rebranding is a timely acknowledgment that media is becoming a technology-driven endeavor. For editors and contributors—such as those within the DDD team—this suggests a future where editorial content is increasingly informed by high-level data trends and sophisticated market intelligence.

4. A Template for M&A

The successful transition from a multi-branded entity to a unified parent brand provides a blueprint for how private-equity-backed media firms can manage growth. By maintaining the "editorial firewall" that protects the credibility of brands like Drug Discovery & Development, Arrowfly is demonstrating that scale does not have to come at the expense of trust.


Conclusion: The Horizon for Arrowfly

As Arrowfly moves forward, the industry will be watching to see how the company leverages its new identity to further penetrate the healthcare and engineering sectors. The challenge for modern B2B media is to remain relevant in a world of rapid technological change. With its deep bench of editorial expertise, a robust event strategy, and a new corporate structure designed for agility, Arrowfly appears well-positioned to maintain its leadership role.

For the professionals in drug discovery, clinical research, and medical innovation, the message is clear: the source they rely on for daily intelligence remains the same, but it is now supported by a more robust, unified, and ambitious parent organization. As the company looks toward the future, the name "Arrowfly" suggests a trajectory of speed, focus, and upward momentum—qualities that the firm clearly hopes to embody as it navigates the next chapter of the B2B media revolution.

For further information regarding the corporate structure, portfolio expansion, or partnership opportunities, industry professionals are encouraged to visit the official Arrowfly website.

About the Author

Nana

Author

View All Posts

Post navigation

Previous: The Silent Burden: Addressing the Unique Mental Health Challenges of Previvors
Next: Moving Through the Storm: The Vital Role of Physical Activity During Chemotherapy

Related Stories

biotech-market-pulse-regulatory-hurdles-alzheimers-breakthroughs-and-strategic-mergers
  • Chemotherapy and Targeted Therapy

Biotech Market Pulse: Regulatory Hurdles, Alzheimer’s Breakthroughs, and Strategic Mergers

Asro July 30, 2026
the-panss-paradox-inside-maplights-volatile-market-reckoning-and-the-future-of-schizophrenia-treatment
  • Chemotherapy and Targeted Therapy

The "PANSS" Paradox: Inside MapLight’s Volatile Market Reckoning and the Future of Schizophrenia Treatment

Reynand Wu July 30, 2026
weekly-oral-hiv-regimen-gilead-and-mercks-new-frontier-in-antiretroviral-therapy
  • Chemotherapy and Targeted Therapy

Weekly Oral HIV Regimen: Gilead and Merck’s New Frontier in Antiretroviral Therapy

Ammar Sabilarrohman July 30, 2026

Recent Posts

  • Biotech Market Pulse: Regulatory Hurdles, Alzheimer’s Breakthroughs, and Strategic Mergers
  • The Subsidy Cliff: ACA Marketplace Enrollment Drops for First Time in Seven Years
  • Advocacy at the Precipice: METAvivor Challenges Proposed Federal Funding Rescissions for PCORI
  • The Three-Minute Reset: How Micro-Yoga Is Solving the Modern Stress Crisis
  • Revolutionizing Breast Cancer Screening: Landmark WISDOM Study Advocates for Personalized, Risk-Based Approaches Over Universal Mammograms

Recent Comments

No comments to show.

Archives

  • July 2026
  • June 2026
  • May 2026
  • September 2025
  • August 2025
  • July 2025

Categories

  • Breast Cancer Legislation and Policy
  • Breast Cancer Prevention and Lifestyle
  • Breast Cancer Surgery and Reconstruction
  • Chemotherapy and Targeted Therapy
  • Clinical Oncology Education
  • Clinical Radiology and Imaging
  • Genomics and Precision Medicine
  • Global Breast Cancer Awareness
  • Hormone Therapy and Endocrinology
  • Integrative Oncology and Holistic Care
  • Medical Research and Clinical Trials
  • Metastatic Breast Cancer Research
  • Patient Advocacy and Support
  • Psychosocial Support and Mental Health
  • Radiation Oncology
  • Survivorship and Post-Treatment
  • Treatment Innovations

You may have missed

biotech-market-pulse-regulatory-hurdles-alzheimers-breakthroughs-and-strategic-mergers
  • Chemotherapy and Targeted Therapy

Biotech Market Pulse: Regulatory Hurdles, Alzheimer’s Breakthroughs, and Strategic Mergers

Asro July 30, 2026
the-subsidy-cliff-aca-marketplace-enrollment-drops-for-first-time-in-seven-years
  • Breast Cancer Legislation and Policy

The Subsidy Cliff: ACA Marketplace Enrollment Drops for First Time in Seven Years

Ammar Sabilarrohman July 30, 2026
advocacy-at-the-precipice-metavivor-challenges-proposed-federal-funding-rescissions-for-pcori
  • Patient Advocacy and Support

Advocacy at the Precipice: METAvivor Challenges Proposed Federal Funding Rescissions for PCORI

Lina Irawan July 30, 2026
the-three-minute-reset-how-micro-yoga-is-solving-the-modern-stress-crisis
  • Integrative Oncology and Holistic Care

The Three-Minute Reset: How Micro-Yoga Is Solving the Modern Stress Crisis

Nana July 30, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Copyright © All rights reserved. | MoreNews by AF themes.